Presentation is loading. Please wait.

Presentation is loading. Please wait.

DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i. e

Published byAntti Salo Modified over 5 years ago

Similar presentations

Presentation on theme: "DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i. e"— Presentation transcript:

1 DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i. e
DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i.e., hyperkalemia with metabolic acidosis and suppressed urinary ammonia excretion. DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i.e., hyperkalemia with metabolic acidosis and suppressed urinary ammonia excretion. Plasma electrolytes and urine studies were obtained in DCT-CA-SPAK and WT mice before any experimental therapy. n=16 for DCT-CA-SPAK mice and 26 for WT mice for measurements of plasma K+ and bicarbonate and urine ammonia and pH, and 16 for each genotype for measurement of urine titratable acid and sum of urine ammonia and titratable acid. Amm + TA, urine ammonia plus titratable acid; DCT-CA-SPAK, mice with early DCT-specific over-expression of constitutively active SPAK; WT, wild-type mice. Autumn N. Harris et al. JASN 2018;29: ©2018 by American Society of Nephrology

Download ppt "DCT-CA-SPAK mice exhibit characteristics of Type 4 RTA, i. e"

Similar presentations

Metabolic Acidosis Bonnie Cramer December 11, 2008.

Metabolic Acidosis Bonnie Cramer December 11, 2008.
Dr. Saidunnisa Professor Of Biochemistry Acid-Base regulation.

Dr. Saidunnisa Professor Of Biochemistry Acid-Base regulation.
Renal Control of Acid-Base Balance The kidneys control acid-base balance by excreting either acidic or basic urine Excreting acidic urine reduces the amount.

Renal Control of Acid-Base Balance The kidneys control acid-base balance by excreting either acidic or basic urine Excreting acidic urine reduces the amount.
Renal control of acid base balance

Renal control of acid base balance
Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates.

Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates.
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.

Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.

Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.

Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.
Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];
Reduced cell motility and expression of phosphorylated FAK in a fibroblast cell line of an individual with T3257I mutation. Reduced cell motility and expression.

Reduced cell motility and expression of phosphorylated FAK in a fibroblast cell line of an individual with T3257I mutation. Reduced cell motility and expression.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.

Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Similar presentations

Ads by Google